Literature DB >> 22197354

Urethra sparing - potential of combined Nickel-Titanium stent and intensity modulated radiation therapy in prostate cancer.

Jakob Borup Thomsen1, Dennis Tideman Arp, Jesper Carl.   

Abstract

BACKGROUND AND
PURPOSE: To investigate a novel method for sparing urethra in external beam radiotherapy of prostate cancer and to evaluate the efficacy of such a treatment in terms of tumour control using a mathematical model.
MATERIALS AND METHODS: This theoretical study includes 20 patients previously treated for prostate cancer using external beam radiotherapy. All patients had a Nickel-Titanium (Ni-Ti) stent inserted into the prostate part of urethra. The stent has been used during the treatment course as an internal marker for patient positioning prior to treatment. In this study the stent is used for delineating urethra while intensity modulated radiotherapy was used for lowering dose to urethra. Evaluation of the dose plans were performed using a tumour control probability model based on the concept of uniform equivalent dose.
RESULTS: The feasibility of the urethra dose reduction method is validated and a reduction of about 17% is shown to be possible. Calculations suggest a nearly preserved tumour control probability.
CONCLUSIONS: A new concept for urethra dose reduction is presented. The method relies on the use of a Ni-Ti stent as a fiducial marker combined with intensity modulated radiotherapy. Theoretical calculations suggest preserved tumour control.
Copyright © 2011 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22197354     DOI: 10.1016/j.radonc.2011.11.015

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  5 in total

Review 1.  Evolution of advanced technologies in prostate cancer radiotherapy.

Authors:  Nicholas G Zaorsky; Amy S Harrison; Edouard J Trabulsi; Leonard G Gomella; Timothy N Showalter; Mark D Hurwitz; Adam P Dicker; Robert B Den
Journal:  Nat Rev Urol       Date:  2013-09-10       Impact factor: 14.432

2.  Randomized phase II trial of urethral sparing intensity modulated radiation therapy in low-risk prostate cancer: implications for focal therapy.

Authors:  Jeffrey Vainshtein; Eyad Abu-Isa; Karin B Olson; Michael E Ray; Howard M Sandler; Dan Normolle; Dale W Litzenberg; Kathryn Masi; Charlie Pan; Daniel A Hamstra
Journal:  Radiat Oncol       Date:  2012-06-09       Impact factor: 3.481

3.  A treatment planning study of urethra-sparing intensity-modulated proton therapy for localized prostate cancer.

Authors:  Takaaki Yoshimura; Kentaro Nishioka; Takayuki Hashimoto; Kazuya Seki; Shouki Kogame; Sodai Tanaka; Takahiro Kanehira; Masaya Tamura; Seishin Takao; Taeko Matsuura; Keiji Kobashi; Fumi Kato; Hidefumi Aoyama; Shinichi Shimizu
Journal:  Phys Imaging Radiat Oncol       Date:  2021-10-08

4.  Visualizing the urethra by magnetic resonance imaging without usage of a catheter for radiotherapy of prostate cancer.

Authors:  Takaaki Yoshimura; Kentaro Nishioka; Takayuki Hashimoto; Taro Fujiwara; Kinya Ishizaka; Hiroyuki Sugimori; Shoki Kogame; Kazuya Seki; Hiroshi Tamura; Sodai Tanaka; Yuto Matsuo; Yasuhiro Dekura; Fumi Kato; Hidefumi Aoyama; Shinichi Shimizu
Journal:  Phys Imaging Radiat Oncol       Date:  2021-03-26

5.  The urethral position may shift due to urethral catheter placement in the treatment planning for prostate radiation therapy.

Authors:  Yasuhiro Dekura; Kentaro Nishioka; Takayuki Hashimoto; Naoki Miyamoto; Ryusuke Suzuki; Takaaki Yoshimura; Ryuji Matsumoto; Takahiro Osawa; Takashige Abe; Yoichi M Ito; Nobuo Shinohara; Hiroki Shirato; Shinichi Shimizu
Journal:  Radiat Oncol       Date:  2019-12-12       Impact factor: 3.481

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.